PPAR Agonists for Treatment of PBC

Author(s):

Nancy Reau, MD,John Vierling, MD, FACP, FAASLD, AGAF

Key Takeaways

PPAR agonists are approved for PBC management, either with UDCA or as monotherapy for UDCA-intolerant patients.
These agents modulate lipid metabolism, inflammation, and fibrosis by activating peroxisome proliferator-activated receptors.
Newer PPAR agonists may target multiple PPAR subtypes, unlike fibrates which primarily target PPAR-alpha.
FDA approval highlights the clinical importance of PPAR agonists, offering alternative treatment for PBC patients with limited options.

The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.

EP: 1.Pathophysiology of PBC

EP: 2.Presentation and Diagnosis of PBC

EP: 3.Differential Diagnosis of PBC

EP: 4.Disease Progression and Extrahepatic Manifestations of PBC

EP: 5.Second-Line Treatments and Management of Symptoms in PBC

EP: 6.Treatment Goals and First-Line Therapy in PBC

EP: 7.Seladelpar for Treatment of PBC

Now Viewing

EP: 8.PPAR Agonists for Treatment of PBC

Video content above is prompted by the following:

We now have FDA-approved PPAR agonists for the management of PBC in combination with UDCA or as monotherapy for patients who are intolerant to UDCA. What is the scientific basis for use of PPAR agonists in PBC? And how are these different than fibrates?